[go: up one dir, main page]

WO2003086470A3 - Smac-peptides as therapeutics against cancer and autoimmune diseases - Google Patents

Smac-peptides as therapeutics against cancer and autoimmune diseases Download PDF

Info

Publication number
WO2003086470A3
WO2003086470A3 PCT/EP2003/004039 EP0304039W WO03086470A3 WO 2003086470 A3 WO2003086470 A3 WO 2003086470A3 EP 0304039 W EP0304039 W EP 0304039W WO 03086470 A3 WO03086470 A3 WO 03086470A3
Authority
WO
WIPO (PCT)
Prior art keywords
smac
cancer
cells
autoimmune diseases
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/004039
Other languages
French (fr)
Other versions
WO2003086470A2 (en
Inventor
Klaus Michael Debatin
Simone Fulda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02008199A external-priority patent/EP1354952A1/en
Priority claimed from EP02015499A external-priority patent/EP1354953A1/en
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to AU2003236211A priority Critical patent/AU2003236211A1/en
Priority to JP2003583486A priority patent/JP2005536457A/en
Priority to EP03722503A priority patent/EP1495124A2/en
Priority to US10/511,037 priority patent/US20050222387A1/en
Publication of WO2003086470A2 publication Critical patent/WO2003086470A2/en
Publication of WO2003086470A3 publication Critical patent/WO2003086470A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to the use of Smac to sensitize different tumors and self-reactive immune cells to various pro-apoptosic stimuli, in that the cells subsequently undergo apoptosis. Therefore, Smac can be used as a compound for the manufacture of a medicament for the treatment of cancer and autoimmune diseases. Sensitization of the cells is achieved either by applying a cell-permeable form of Smac combined with known anticancer agents or by overexpression of the protein. It is an object of the invention to provide a new method in cancer and autoimmune disease therapy by using Smac agonists for apoptosis regulation. Thus, Smac agonists represent novel promising cancer and autoimmune disease therapeutics to potentiate the efficacy of cytotoxic therapies even in resistant tumors and immune cells.
PCT/EP2003/004039 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases Ceased WO2003086470A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003236211A AU2003236211A1 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
JP2003583486A JP2005536457A (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics for cancer and autoimmune diseases
EP03722503A EP1495124A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
US10/511,037 US20050222387A1 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02008199A EP1354952A1 (en) 2002-04-17 2002-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
EP02008199.8 2002-04-17
EP02015499A EP1354953A1 (en) 2002-04-17 2002-07-12 Smac-peptides as therapeutics against cancer and autoimmune diseases
EP02015499.3 2002-07-12
EP03722503A EP1495124A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases

Publications (2)

Publication Number Publication Date
WO2003086470A2 WO2003086470A2 (en) 2003-10-23
WO2003086470A3 true WO2003086470A3 (en) 2004-05-06

Family

ID=33458041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004039 Ceased WO2003086470A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases

Country Status (2)

Country Link
EP (1) EP1495124A2 (en)
WO (1) WO2003086470A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
EP1778718B1 (en) 2004-07-02 2014-10-08 Genentech, Inc. Inhibitors of iap
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
JP2009512719A (en) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド IAPBIR domain binding compound
RU2451025C2 (en) 2005-12-19 2012-05-20 Дженентек, Инк. Iap inhibitors
TWI504597B (en) 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
BRPI0708942A2 (en) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc apoptosis promoting compound, use and method of production thereof and pharmaceutical composition
JP2010513561A (en) 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド IAP imidazopyridine inhibitors
CA2684169C (en) 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
MX2011002936A (en) 2008-09-25 2011-04-11 Cephalon Inc Liquid formulations of bendamustine.
WO2011059763A2 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
MX340870B (en) 2010-02-12 2016-07-27 Pharmascience Inc Iap bir domain binding compounds.
CN110636853B (en) * 2017-05-19 2024-10-18 佐治亚州立大学研究基金会公司 Recombinant oncolytic virus

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO2000029427A2 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2001046070A (en) * 1999-08-05 2001-02-20 Japan Science & Technology Corp Transporters using cystine, basic amino acids and neutral amino acids as substrates and genes thereof
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001049719A2 (en) * 2000-01-06 2001-07-12 Board Of Regents, The University Of Texas System Activators of caspases
US6306613B1 (en) * 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
EP0903408A2 (en) * 1992-08-21 1999-03-24 Biogen, Inc. Tat-derived transport polypeptide
US6306613B1 (en) * 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO2000029427A2 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2001046070A (en) * 1999-08-05 2001-02-20 Japan Science & Technology Corp Transporters using cystine, basic amino acids and neutral amino acids as substrates and genes thereof
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001049719A2 (en) * 2000-01-06 2001-07-12 Board Of Regents, The University Of Texas System Activators of caspases
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1, 7 December 2001 (2001-12-07), ORLANDO, FLORIDA, USA *
92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001 *
93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA; April 06-10, 2002 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2001, ENDO, HITOSHI ET AL: "Cysteine, basic and neutral amino acid transporter BAT1 from rat and human activated by rBAT, cDNA, and recombinant expression", XP002204777, retrieved from STN Database accession no. 134:174559 HCA *
DEROSSI D ET AL: "TROJAN PEPTIDES: THE PENETRATIN SYSTEM FOR INTRACELLULAR DELIVERY", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, vol. 8, February 1998 (1998-02-01), pages 84 - 87, XP002940006, ISSN: 0962-8924 *
EKERT P G ET AL.: "DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9", JOURNAL OF CELL BIOLOGY, vol. 153, no. 3, 30 April 2001 (2001-04-30), pages 483 - 490, XP002272041, ISSN: 0021-9525 *
FISCHER P M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIP OF TRUNCATED AND SUBSTITUTED ANALOGUES OF THE INTRACELLULAR DELIVERY VECTOR PENETRATIN", JOURNAL OF PEPTIDE RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 55, no. 2, February 2000 (2000-02-01), pages 163 - 172, XP000899124, ISSN: 1397-002X *
FULDA SIMONE ET AL: "Release of Smac from mitochondria bypasses the Bcl-2 inhibition in type II cells and sensitizes for death receptor or drug-induced apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), pages 552, XP002251122, ISSN: 0197-016X *
FULDA SIMONE ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), pages 808 - 815, XP002251127, ISSN: 1078-8956 *
FULDA SIMONE ET AL: "Smac peptides or Smac gene transfer as a novel strategy to overcome resistance against TRAIL- or drug-induced apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 527 - 528, XP002251124, ISSN: 0197-016X *
FULDA SIMONE ET AL: "Smac release from mitochondria bypasses the Bcl-2 inhibition and sensitizes tumor cells for death receptor or drug-induced apoptosis.", BLOOD NOVEMBER 16, 2001, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), pages 572a - 573a, XP002251123, ISSN: 0006-4971 *
HOLCIK M ET AL: "TRANSLATION UPREGULATION OF X-LINKED INHIBITOR OF APOPTOSIS (XIAP) INCREASES RESISTANCE TO RADIATION INDUCED CELL DEATH", ONCOGENE, vol. 19, no. 36, 24 August 2000 (2000-08-24), pages 4174 - 4177, XP008007068, ISSN: 0950-9232 *
IGNEY FREDERIK H ET AL: "Death and anti-death: Tumour resistance to apoptosis.", NATURE REVIEWS CANCER, vol. 2, no. 4, 20 April 2002 (2002-04-20), pages 277 - 288, XP002251126, ISSN: 1474-175X *
J. SILKE ET AL.: "The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites", JOURNAL OF CELL BIOLOGY, vol. 157, no. 1, 1 April 2002 (2002-04-01), pages 115 - 124, XP002272040, ISSN: 0021-9525 *
JOHNSTONE RICKY W ET AL: "Apoptosis: A link between cancer genetics and chemotherapy.", CELL, vol. 108, no. 2, 25 January 2002 (2002-01-25), pages 153 - 164, XP002251125, ISSN: 0092-8674 *
SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075 *
SRINIVASULA S M ET AL: "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis", NATURE, vol. 410, 1 March 2001 (2001-03-01), pages 112 - 116, XP002962286, ISSN: 0028-0836 *
VERHAGEN A M ET AL: "HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 1, 4 January 2002 (2002-01-04), pages 445 - 454, XP002957689, ISSN: 0021-9258 *
VERHAGEN ANNE M ET AL: "Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins", CELL, vol. 102, no. 1, 7 July 2000 (2000-07-07), pages 43 - 53, XP002175397, ISSN: 0092-8674 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base

Also Published As

Publication number Publication date
EP1495124A2 (en) 2005-01-12
WO2003086470A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003086470A3 (en) Smac-peptides as therapeutics against cancer and autoimmune diseases
PH12020552065A1 (en) Ibrutinib combination therapy
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MX2007004551A (en) Thiadiazole compounds and methods of use.
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
NZ544472A (en) Compounds and therapeutical use thereof
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2018141002A3 (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
EA201070013A1 (en) SALTS of the JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) -1H-PYRAZOL-1-IL) -3-CYCLOPENTYL-PROPHANNITRY
MXPA05012155A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
MXPA05008478A (en) Substituted heterocycles.
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
EP2004637A1 (en) Substituted ring fused azines and their use in cancer therapy
CY1110329T1 (en) PEGylated Liposomal Doxorubicin in Combination with Ectein Succinin 743
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
TNSN07294A1 (en) Treatment of metastasized tumors
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
GB0416508D0 (en) Therapeutic agents
WO2007015935A8 (en) Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
IL164564A0 (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003583486

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003722503

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003722503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10511037

Country of ref document: US